- Home»
- The Billing Beat Newsletter»
- BCBS – Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, HER2, PD-L1, TMB)- update
BCBS – Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, HER2, PD-L1, TMB)- update
February 5, 2023Effective 2/9/2023
Update Coding Section
§ Added: 81445, 81455, 88341 and 0326U
§ Removed Coding bullet
o ICD-10-CM does not have specific coding for non-small-cell lung cancer. The malignant neoplasm of lung codes above would be used.
The source page for this article has moved or has expired.
Please visit the Billing Beat News or Beyond Billing Blog for relevant information or search our site for specific information related to this article.
Original source URL:
https://www.bcbsks.com/medical-policies/somatic-biomarker-testing-including-liquid-biopsy-targeted-treatment-and